Clinical trials: HAM/TSP
Tropical Spastic Paraparesis
MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
This study will use three different magnetic resonance imaging (MRI) techniques to study HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/STP)-a disease of slowly progressive weakness in the legs.
- Trial name
- NCT00034723
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I-associated Myelopathy
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
- Trial name
- NCT00272480
- Testing
- Zidovudine/lamivudine
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Imperial College London
HTLV-I Infection
Raltegravir for HAM/TSP
Background: Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infection of the spinal cord.
- Trial name
- NCT01867320
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I Infection, Tropical Spastic Paraparesis
Evaluation of Patients With HAM/TSP
Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus.
- Trial name
- NCT00001778
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV I Associated Myelopathy
Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
HAM/TSP is a chronic disease of the spinal cord, caused by a virus called HTLV-I. Worldwide approximately 20 million persons are infected.Infection with HTLV-I is lifelong, and about 3% of infected persons will develop this…
- Trial name
- HAM05 (NCT00773292)
- Testing
- ciclosporin
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
HTLV-I-Associated Myelopathy
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Reversible acetylation of the histone tails plays an important role in the control of specific gene expression. Mounting evidence has established that histone deacetylase inhibitors such as Valproic Acid (VPA)selectively induce…
- Trial name
- VALPROHAM (NCT00519181)
- Testing
- Valproic Acid
- Volunteers
- 19 people
- Sponsor
- University Hospital Pierre Zobda-Quitman
Paraparesis Spastic Tropical
Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)
Is the valproic acid efficacy to treat TSP/HAM
- Trial name
- NCT00681980
- Testing
- Valproic acid, costicosteroids, valproid acid plus corticosteroids
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
HAM/TSP
Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
Background: HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare, progressive disease. It occurs in some people infected with the HTLV-1 virus.
- Trial name
- NCT04799288
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I-associated Myelopathy
The HAM Infliximab Study
An open-label, non-randomised, uncontrolled, proof-of-concept study of eight patients with 'definite' HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
- Trial name
- HAM06 (NCT00823641)
- Testing
- Infliximab
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
HAM/TSP, HTLV-1 Secondary Myelopathy
Pilates Method in People With HAM/TSP
Individuals with HTLV-1 secondary myelopathy (HAM/TSP) may have motor and sensory alterations, which may result in reduced functional performance and consequent risk of falls.
- Conditions
- HAM/TSP, HTLV-1 Secondary Myelopathy, Balance, Gait Balance
- Trial name
- NCT04830319
- Testing
- Pilates Method, task-oriented training protocol
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Pedreira, Érika, M.D.
HTLV-1
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- Trial name
- NCT00076843
- Testing
- Hu MiK-Beta-1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I-Associated Myelopathy
Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
An open-label, non-randomised, uncontrolled, proof-of-concept study of patients with HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
- Trial name
- NCT01343355
- Testing
- Tamibarotene
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- St. Marianna University School of Medicine